Abstract
Primary myelodysplastic syndromes (MDS) occur in the absence of exposure to ionizing radiation, chemotherapeutic agents or myelotoxic drugs, whereas secondary MDS occurs in the presence of such exposure. We encountered 4 patients among 217 patients on hydroxychloroquine for rheumatological conditions in 2005 diagnosed with MDS. Two patients were male and two were female; the median age was 69.75 years, (range 65–76). The dose of hydroxychloroquine for all patients was 400 mg daily with median treatment duration of 10.5 years and a range of 6–16. All patients had bone marrow biopsy confirmation of the diagnosis of MDS. The incidence of MDS in a group older than 70 years ranges from 15 to 50/100,000 persons per year. The diagnosis of 4 cases of MDS among 217 patients in 1 year is approximately 123–137-fold higher than the risk of MDS in the general population aged more than 70 years (P < 0.001) and suggests that long-term treatment with hydroxychloroquine is associated with an increased risk of developing secondary MDS.
References
Fox RI (1993) Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 23(2 Suppl 1):82–91
Sole F, Espinet B, Sanz GF et al (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108:346–356
Kerkhofs H, Hermans J, Haak HL, Leeksma CH (1987) Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65:73–81
Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340:1649–1660
Hofmann WK, Koeffler HP (2005) Myelodysplastic syndrome. Annu Rev Med 56:1–16
Huebner G, Karthaus M, Pethig K, Freund M, Ganser A (2000) Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. Transplantation 70:688–690
Renneboog B, Hansen V, Heimann P et al (1996) Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Br J Haematol 92:696–698
Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81(1):104–130
Aul C, Germing U, Gattemann N et al (1998) Increasing incidence of myelodysplastic syndrome: real or fictitious? Leuk Res 22:93–100
MDS foundation (http://www.mds-foundation.org)
Knipp S, Hildebrandt B, Richter G et al (2005) Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 90:691–693
Agomo PU, Idigo JC, Afolabi BM (1992) “Antimalarial” medicinal plants and their impact on cell populations in various organs of mice. Afr J Med Med Sci 21(2):39–46
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muslimani, A.A., Spiro, T.P., Chaudhry, A.A. et al. Secondary myelodysplastic syndrome after hydroxychloroquine therapy. Ann Hematol 86, 531–534 (2007). https://doi.org/10.1007/s00277-006-0249-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-006-0249-3